The New Zealand government has announced an additional investment of NZ$60 million ($42 million) towards new medicines.
The news was welcomed by Medicines New Zealand, the trade group for the country’s pharmaceutical industry, which has complained of an unduly slow process for decisions on reimbursement.
Last week, the group used its annual report to draw attention to the fact that the list of medicines awaiting a decision from New Zealand’s Pharmaceutical Management Agency, or PHARMAC, had risen from 81 to 94 during 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze